Abstract
Ten years have passed since the publication of the first study of administration of liraglutide to obese patients without diabetes. Surprisingly, liraglutide has only become available in this indication in the course of 2018, both in Europe and domestically.
Liraglutide is well tolerated and, unlike in diabetes treatment, can be administered in doses of up to 3 mg/day as one daily injection. It has the same efficacy in patients with prediabetes and in those without this condition.
It has profoundly improved manifestations of sleep apnoea and is effective also in patients adapted to low food intake, i.e. those who have succeeded in losing weight using regimen measures only. Therefore, liraglutide is the most effective anti-obesity drug today, opening other obesity treatment options as well with incretin analogues.